Literature DB >> 26557983

Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.

Kentaro Kawabe1, Shinichiro Ochi2, Yuta Yoshino2, Yoko Mori2, Hiroshi Onuma3, Haruhiko Osawa3, Yoshiki Hosoda4, Shu-Ichi Ueno2.   

Abstract

BACKGROUND: Common adverse effects of atypical antipsychotic treatments for schizophrenia are weight gain and lipid metabolism abnormality. We aimed to identify the signs of metabolic problems with continuous atypical antipsychotic treatment for schizophrenia over a 2-year period.
METHODS: The participants were 68 schizophrenic patients (29 males, 39 females; ages 53.4 ± 13.5 years old). Changes in carbohydrate metabolism and changes in physical characteristics were studied over a 2-year period. In addition, functional single nucleotide polymorphisms in the transcriptional regulatory region of the resistin gene were examined.
RESULTS: We found no changes in the mental state of the participants over a 2-year period. Patients did show a significant decrease in total cholesterol and hemoglobin A1c levels, although physical changes such as body mass index and abdominal girth, were not observed. The amount of resistin may not be associated with mental states and physical parameters.
CONCLUSIONS: We could not find physical factors related to metabolic changes of antipsychotics in this 2-year study. However, several psychological factors, such as health-related thoughts and behaviors, should be studied in the future.

Entities:  

Keywords:  antipsychotics; diabetes; metabolic syndrome; resistin; schizophrenia

Year:  2015        PMID: 26557983      PMCID: PMC4622120          DOI: 10.1177/2045125315596697

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  19 in total

1.  The hormone resistin links obesity to diabetes.

Authors:  C M Steppan; S T Bailey; S Bhat; E J Brown; R R Banerjee; C M Wright; H R Patel; R S Ahima; M A Lazar
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

2.  Prevalence of metabolic syndrome among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Yasushi Sato; Takashi Umeda; Ikuko Kishida; Hakuei Yamashita; Manabu Saito; Hanako Furukori; Taku Nakagami; Mitsunori Hatakeyama; Shigeyuki Nakaji; Sunao Kaneko
Journal:  Schizophr Res       Date:  2010-09-17       Impact factor: 4.939

3.  Two new criteria of the metabolic syndrome: prevalence and the association with brachial-ankle pulse wave velocity in Japanese male workers.

Authors:  Koichi Miyaki; Asako Hara; Mariko Naito; Toru Naito; Takeo Nakayama
Journal:  J Occup Health       Date:  2006-03       Impact factor: 2.708

4.  The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3.

Authors:  Haruhiko Osawa; Kazuya Yamada; Hiroshi Onuma; Akiko Murakami; Masaaki Ochi; Hiroko Kawata; Tatsuya Nishimiya; Toshiyuki Niiya; Ikki Shimizu; Wataru Nishida; Mitsuru Hashiramoto; Azuma Kanatsuka; Yasuhisa Fujii; Jun Ohashi; Hideichi Makino
Journal:  Am J Hum Genet       Date:  2004-08-26       Impact factor: 11.025

5.  A at single nucleotide polymorphism-358 is required for G at -420 to confer the highest plasma resistin in the general Japanese population.

Authors:  Hiroshi Onuma; Yasuharu Tabara; Ryoichi Kawamura; Takashi Tanaka; Jun Ohashi; Wataru Nishida; Yasunori Takata; Masaaki Ochi; Kazuya Yamada; Ryuichi Kawamoto; Katsuhiko Kohara; Tetsuro Miki; Hideichi Makino; Haruhiko Osawa
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

Review 6.  Physical health monitoring of patients with schizophrenia.

Authors:  Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

Review 7.  Schizophrenia, the metabolic syndrome and diabetes.

Authors:  R I G Holt; R C Peveler; C D Byrne
Journal:  Diabet Med       Date:  2004-06       Impact factor: 4.359

8.  Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.

Authors:  A Tschoner; J Engl; M Rettenbacher; M Edlinger; S Kaser; T Tatarczyk; M Effenberger; J R Patsch; W W Fleischhacker; C F Ebenbichler
Journal:  Pharmacopsychiatry       Date:  2009-01-19       Impact factor: 5.788

9.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

Review 10.  The current biology of resistin.

Authors:  Claire M Steppan; Mitchell A Lazar
Journal:  J Intern Med       Date:  2004-04       Impact factor: 8.989

View more
  3 in total

1.  Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study.

Authors:  Yongmin Kim; Sheng-Min Wang; Kyung-Phil Kwak; Ho-Kyoung Yoon; Chi-Un Pae; Jung-Jin Kim; Won-Myong Bahk
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

2.  GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice.

Authors:  Brend Ray-Sea Hsu; Shin-Huei Fu
Journal:  Toxicol Rep       Date:  2016-04-27

3.  Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics: Preliminary study.

Authors:  Rupali Rohatgi; Ravi Gupta; Rajat Ray; Vinita Kalra
Journal:  Indian J Psychiatry       Date:  2018 Oct-Dec       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.